Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Target |
Mechanism HIF-PHs inhibitors |
Originator Org. |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date17 Dec 2018 |
Target |
Mechanism H+/K+ ATPase blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date26 Dec 2014 |
Start Date17 Jun 2024 |
Sponsor / Collaborator |
Start Date03 Jun 2024 |
Sponsor / Collaborator |
Start Date17 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Vonoprazan Fumarate ( H+/K+ ATPase ) | Gastroesophageal Reflux More | Phase 1 |
Empagliflozin/metformin Hydrochloride ( PRKAB1 x SGLT2 ) | Diabetes Mellitus, Type 2 More | Phase 1 |
Roxadustat ( HIF-PHs ) | chronic renal failure anemia More | Phase 1 |
Deoxypodophyllotoxin ( Tubulin ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
Azilsartan Kamedoxomil ( AT1R ) | Hypertension More | Phase 1 |